<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03862859</url>
  </required_header>
  <id_info>
    <org_study_id>DANWARD 1.21</org_study_id>
    <secondary_id>2018-000484-86</secondary_id>
    <nct_id>NCT03862859</nct_id>
  </id_info>
  <brief_title>The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis</brief_title>
  <acronym>DANWARD</acronym>
  <official_title>The Danish Warfarin-Dialysis Study: Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis - A Nationwide Parallel-group Open Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicholas Carlson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the appropriateness of initiating oral anticoagulation for stroke
      risk reduction in dialysis populations with atrial fibrillation. Specifically, the study will
      assess the overall safety, tolerability, and efficacy of initiating treatment with Warfarin
      in patients with end-stage renal disease on dialysis and de novo atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data pertaining to the tolerability, safety, and benefit of initiating anticoagulation for
      stroke risk reduction in patients with end-stage renal disease and atrial fibrillation
      remains conflicting and insufficient. Patients on dialysis continue to be routinely excluded
      from randomized controlled trials, and evidence from observational studies is plausibly
      biased. The main objective of the following parallel-group open randomized clinical trial
      presents a nationwide study aimed at investigating the benefit, tolerability, and safety of
      initiating warfarin versus no treatment in patients with atrial fibrillation on dialysis. The
      anticipated results from this project will provide conclusive evidence as to the
      appropriateness of initiating oral anticoagulation for stroke risk reduction in dialysis
      populations with atrial fibrillation with direct effects on clinical management and
      international guidelines pertaining to these patients.

      The study is planned as a multicentre, randomized, open label, parallel group trial with
      planned inclusion of a total of 718 patients (359 patients per arm).Dialysis-treated patients
      with end-stage renal disease with de novo diagnosis of paroxysmal, persistent, or permanent
      atrial fibrillation will be enrolled and randomized to either treatment with warfarin or no
      treatment. Randomization with be attained using a 1:1 allocation as per a computer-generated
      randomization schedule stratified by gender, age by decade, and center using permuted blocks
      of random sizes. Study participants will be allocated to treatment in accordance with the
      randomization for the full duration of the trial i.e. at a minimum one year following
      randomization, and followed with regular monitoring for the the primary efficacy outcome of
      ischemic stroke or death due to ischemic or unspecified stroke and the primary safety outcome
      of major bleeding defined in accordance with the International Society on Thrombosis and
      Hemostasis definition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multicentre, randomized, open label, parallel group study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None (Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy outcome - Number of participants with transient ischemic attack, fatal and non-fatal ischaemic or unspecific stroke</measure>
    <time_frame>From randomization to end of observation - up to 4 years</time_frame>
    <description>Any transient ischemic attack, fatal and non-fatal ischaemic or unspecific stroke or death attributable to either ischemic or undefined stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety outcome - Number of participants with fatal or non-fatal major bleeding</measure>
    <time_frame>From randomization to end of observation - up to 4 years</time_frame>
    <description>Any major bleeding as defined in accordance with the International Society on Thrombosis and Hemostasis definition pertaining to major bleeding in non-surgical patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with ischemic or unspecified stroke</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Any non-fatal or fatal ischemic stroke or unspecified stroke event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with ischemic stroke</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Any non-fatal or fatal ischemic stroke event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with hemorrhagic stroke</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Any non-fatal or fatal hemorrhagic stroke event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with ischemic or hemorrhagic stroke</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Any non-fatal or fatal ischemic or hemorrhagic stroke event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The combination of any non-fatal stroke and all-cause mortality</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Number of participants with either non-fatal ischemic or hemorrhagic stroke of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The combination of any non-fatal stroke, any non-fatal major bleeding, and all-cause mortality</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Number of participants with either non-fatal ischemic or hemorrhagic stroke, any non-fatal major bleeding as defined in accordance with the International Society on Thrombosis and Hemostasis definition pertaining to major bleeding in non-surgical patients, or death due to any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Discontinuation of the allocated randomized therapy</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Number of participants discontinuing the allocated randomized therapy irrespective of cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with peripheral artery disease</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Any diagnosis of previously unverified peripheral artery disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with fatal or non-fatal acute myocardial infarction</measure>
    <time_frame>From randomization to end of observation - up to 4 years</time_frame>
    <description>Any non-fatal or fatal acute myocardial infarction event</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with calciphylaxis</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Development of calciphylaxis as defined by clinical diagnosis</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants hospitalized due to left-sided heart failure</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Any hospitalization due to left-sided heart failure as defined by de novo LVEF &lt;30% with echocardiographic verification</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of participants with arteriovenous fistula thrombosis</measure>
    <time_frame>From randomization to end of observation - up to 4 years</time_frame>
    <description>Arteriovenous fistula thrombosis in participants dialyzed via an arteriovenous fistula</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with osteoporotic fractures</measure>
    <time_frame>From randomization to end of observation - up to 4 years</time_frame>
    <description>Osteoporotic fractures as defined by low energy fractures of the proximal femur, distal radius, humerus, pelvis, and vertebrae</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">718</enrollment>
  <condition>Atrial Fibrillation and Flutter</condition>
  <condition>Stroke</condition>
  <condition>Major Bleed</condition>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Treatment with Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin with dosing targeting an international normalized ratio of 2-3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Dose adjusted Warfarin targeting an international normalized ratio of 2-3.</description>
    <arm_group_label>Treatment with Warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
    <other_name>Marevan</other_name>
    <other_name>Jantoven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years on chronic dialysis due to end-stage renal disease with de novo
             diagnosis of non-valvular paroxysmal, persistent, or permanent atrial fibrillation as
             documented by an electrocardiogram or an episode of ≥30 seconds on Holter monitor, or
             episodes ≥ 6 minutes on event recorders or any other recording device.

          -  Competence to understand the study rationale, including potential risks and benefits
             associated with treatment, necessary for written informed consent.

        Exclusion Criteria:

          -  CHA2DS2-VASc Score ≤1

          -  Other indications for oral anticoagulation treatment (pulmonary embolism &lt; 6 months,
             deep vein thrombosis &lt;3 months, prior atrial fibrillation, mechanical heart valve
             prosthesis) irrespective of whether treatment is implemented

          -  Ongoing dual antiplatelet treatment

          -  Malignancy (with exception of non-melanoma skin cancer) with recent &lt; 1 year, ongoing,
             or planned curative, or palliative chemo- , radiation-, and/or scheduled surgical
             therapy

          -  Endoscopy with gastrointestinal ulcer &lt;1 month

          -  Esophageal varices

          -  Autoimmune og genetic coagulation disorders

          -  Congenital alactasia, Lapp Lactase deficiency or glucose-galactose malabsorption

          -  Pending spinal tap

          -  Cerebrovascular malformations

          -  Arterial aneurysms

          -  Ulcers or wounds (Wagner grad &gt;1)

          -  Bacterial endocarditis &lt; 3 months

          -  Active bleeding contraindicating anticoagulation

          -  Any non-elective and/or non-ambulant surgery &lt;7 days

          -  Cerebral hemorrhage &lt;4 weeks

          -  Thrombocytopenia (platelet count &lt;100 × 109/L) &lt;30 days.

          -  Severe liver insufficiency (spontaneous international normalized ratio &gt;1.5) &lt;30 days.

          -  Known intolerance to warfarin

          -  Use of hypericum perforatum / St. John's Wort

          -  Uncontrolled hypertension (repeat blood pressure &gt;180/110 mmhg) &lt; 30 days

          -  Uncontrolled hyperthyroidism (thyroid-stimulating hormone &lt;0.1μIU/mL) &lt;30 days

          -  Pregnancy or lactation

          -  Participation in other ongoing intervention trials adjudged to influence study
             outcomes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Carlson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Copenhagen University Hospital Rigshospitalet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunnar H Gislason, Prof MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Danish Heart Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne-Lise Kamper, MD DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nephrology, Copenhagen University Hospital Rigshospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Carlson, MD PhD</last_name>
    <phone>+45 35455827</phone>
    <email>nicholas.carlson.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gunnar H Gislason, Prof MD PhD</last_name>
    <phone>+45 70 25 00 00</phone>
    <email>Gunnar.Gislason@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nephrology, Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Carlson, MD PhD</last_name>
      <phone>+45 35455927</phone>
      <email>nicholas.carlson.01@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Nicholas Carlson, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristine Lindhard Rasmussen, MD</last_name>
      <email>kristine.lindhard.rasmussen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Kristine Lindhard Rasmussen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of nephrology, Nordsjaellands Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisbet Brandi, MD DMSc</last_name>
      <email>lisbet.brandi@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Lisbet Brandi, MD DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Nicholas Carlson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for primary and secondary outcomes measures will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available within 12 months of study completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed, requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

